Melanoma-associated antigen 1; MAGE-1
CAT No: ta-442
Synonyms/Alias:Melanoma-associated antigen 1 (289-298); MAGE-1 (289-298)
MAGE-1 (289-298) is a synthetic peptide corresponding to amino acid residues 289 to 298 of the Melanoma Antigen Gene-1 (MAGE-1) protein, a member of the cancer-testis antigen family. As a well-characterized antigenic epitope, this peptide is widely recognized in tumor immunology and antigen presentation research due to its selective expression in various malignant cells and minimal presence in normal tissues, except for testicular germ cells. The sequence is frequently utilized as a model system for investigating peptide-MHC interactions, T cell recognition, and the molecular mechanisms underlying tumor-specific immune responses. Its defined structure and immunogenic properties make it a valuable tool for dissecting antigen processing pathways and exploring the immunobiology of cancer-associated antigens in experimental settings.
Epitope mapping: Researchers employ MAGE-1 (289-298) peptide in epitope mapping studies to delineate the specific regions of the MAGE-1 protein recognized by cytotoxic T lymphocytes (CTLs). By using this peptide in in vitro assays, scientists can identify the minimal sequence required for T cell receptor engagement and MHC class I binding. Such mapping is essential for understanding the immunodominant features of tumor antigens and supports the rational design of immunological reagents for basic and applied research.
Antigen presentation studies: The peptide serves as an established model for evaluating antigen processing and presentation by major histocompatibility complex (MHC) class I molecules. Its use in cellular assays enables investigation into the efficiency of peptide loading, stability of peptide-MHC complexes, and the influence of various antigen-presenting cell types. These studies provide critical insights into the rules governing immunogenic peptide display and inform the development of improved antigen presentation assays.
T cell activation assays: MAGE-1 (289-298) is frequently utilized to stimulate antigen-specific CD8+ T cells in vitro, facilitating the assessment of T cell function, specificity, and cytolytic activity. By exposing T cells to this defined epitope, researchers can monitor cytokine release, proliferation, and effector responses, contributing to the characterization of T cell repertoires and the identification of immunogenic determinants within tumor antigens. This application is instrumental in evaluating T cell-based immunotherapeutic strategies and understanding the dynamics of anti-tumor immunity.
Peptide-MHC binding studies: The peptide's defined sequence and known HLA-A1 restriction make it a preferred substrate for in vitro MHC binding assays. Researchers can use it to assess the affinity and stability of peptide-MHC complexes, compare the impact of sequence modifications, or benchmark novel computational prediction algorithms. Such studies are fundamental in elucidating the molecular determinants of antigen presentation and optimizing peptide-based reagents for immunological applications.
Immunological assay development: As a well-characterized tumor-associated epitope, MAGE-1 (289-298) is incorporated into various immunological assay platforms, including ELISPOT, flow cytometry, and tetramer staining. Its inclusion allows for the sensitive detection and quantification of antigen-specific T cell responses in experimental systems. This utility is particularly valuable in preclinical research focused on evaluating immune recognition, monitoring vaccine-induced responses, and validating assay performance using a standardized epitope relevant to tumor immunology.
2. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
5. High fat diet and GLP-1 drugs induce pancreatic injury in mice
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More